"The resulting CYPA:drug:KRASG12C #tricomplex inactivated #oncogenic signaling and led to tumor regressions in multiple human cancer models. This inhibitory strategy can be used to target additional #KRAS mutants and other undruggable #cancer drivers."

https://www.science.org/doi/10.1126/science.adg9652